FDA Approves Hyrimoz (adalimumab-adaz), a Biosimilar to Humira Print this page Holzkirchen, Germany, October 31, 2018 – Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar, Hyrimoz (adalimumab-adaz). The FDA granted approval for the treatment of rheumatoid arthritis (RA),… Read More »
Learn how to use essential oils for aromatherapy. Does it seem like everywhere you go these days, someone is talking about essential oils? If you don’t already use them, you might be curious as to why them seem to be all the rage right now. Well, there are tons of reasons why people regularly use… Read More »
Dolutegravir-based treatment was no more effective than treatment based on a 400mg dose of efavirenz, a randomised trial conducted in Cameroon has found. However, almost half of people with very high viral loads taking either regimen had a detectable viral load after 48 weeks, the HIV Glasgow 2018 conference heard. Despite the non-inferiority of efavirenz-based… Read More »